Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ravulizumab

ravulizumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ravulizumab

13 trials tracked of ravulizumab: 11 in phase 3 or 4 and 9 with published results. The most-cited published study has 376 citations.

13Trials tracked
11Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 1 Phase 3 10 Phase 2 1 Phase 1 1
  1. Phase 3 ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Completed · 376 cited
  2. Phase 3 Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Completed · 216 cited
  3. Phase 3 Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis Completed · 214 cited
  4. Phase 3 Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment Completed · 136 cited
  5. Phase 3 ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed · 125 cited
  6. Phase 3 Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Completed · 66 cited
Show 7 more trials
  1. Phase 3 Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Completed · 23 cited
  2. Phase 3 A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria Completed · 11 cited
  3. Phase 3 An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD Completed · 8 cited
  4. Phase 4 Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab Completed
  5. Phase 3 Study of Ravulizumab in Pediatric Participants With HSCT-TMA Completed
  6. Phase 2 Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed
  7. Phase 1 Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
Oncology Meta-analysis
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …
Apr 14, 2026
Case report: Ravulizumab successfully treated COVID-19-triggered complement-mediated TMA in a kidney transplant recipient
Rheumatology
Case report: Ravulizumab successfully treated COVID-19-triggered complement-mediated TMA in a kidney transplant recipient Doctors report a single case where ravulizumab treated a rare blood disorder after COVID-19 in a kidney transplant patient
A case report describes a 75-year-old kidney transplant recipient who developed complement-mediated thrombotic microangiopathy (CM-TMA) trig…
A kidney transplant patient with COVID-19 improved after doctors treated a rare blood disorder with ravulizumab, showing age shouldn't block…
Frontiers Mar 31, 2026